Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Capital Fund Management S.A.

Key Points

• Capital Fund Management S.A. increased its stake in Ultragenyx Pharmaceutical by 40.5% in Q1, acquiring an additional 13,859 shares for a total of 48,084 shares, valued at approximately $1.74 million.
• Several institutional investors have also adjusted their holdings, with GAMMA Investing LLC increasing its stake by 76.2% and Covestor Ltd by 86.8% during the first quarter.
• Ultragenyx recently reported a net revenue of $166.5 million for Q2, which was 13.2% higher year-over-year, and the company's stock has an average analyst rating of "Moderate Buy" with a consensus price target of $81.50.

Capital Fund Management S.A. grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 40.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 48,084 shares of the biopharmaceutical company's stock after buying an additional 13,859 shares during the period. Capital Fund Management S.A. owned 0.05% of Ultragenyx Pharmaceutical worth $1,741,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of RARE. GAMMA Investing LLC boosted its position in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares in the last quarter. ANTIPODES PARTNERS Ltd acquired a new stake in Ultragenyx Pharmaceutical in the first quarter worth about $57,000. Headlands Technologies LLC acquired a new stake in Ultragenyx Pharmaceutical in the first quarter worth about $59,000. Covestor Ltd boosted its holdings in Ultragenyx Pharmaceutical by 86.8% in the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock worth $62,000 after acquiring an additional 795 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth about $82,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded down $0.34 on Friday, reaching $29.96. 1,340,019 shares of the company's stock traded hands, compared to its average volume of 1,472,288. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of -5.42 and a beta of 0.21. The stock has a 50 day moving average price of $30.97 and a 200-day moving average price of $35.15. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.10. The business had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The company's revenue for the quarter was up 13.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares of the company's stock, valued at approximately $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 5.50% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on RARE. Wells Fargo & Company lowered their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. Canaccord Genuity Group lowered their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Guggenheim reaffirmed a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Wedbush lowered their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. Finally, Morgan Stanley lowered their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.